Inhibikase Therapeutics (IKT) Total Current Liabilities (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Total Current Liabilities data on file, last reported at $5.7 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $5.7 million, down 33.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 million (down 33.2% YoY), and the FY2025 annual result was $8.3 million, up 122.33% from the prior year.
• Total Current Liabilities retreated to $5.7 million in Q1 2026 per IKT's latest filing, from $8.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $8.8 million in Q2 2025 and troughed at $2.7 million in Q1 2023.
• A 5-year average of $4.9 million and a median of $3.7 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities jumped 137.53% in 2025, then tumbled 33.2% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $3.7 million in 2022, then decreased by 6.95% to $3.4 million in 2023, then climbed by 8.58% to $3.7 million in 2024, then soared by 122.33% to $8.3 million in 2025, then plunged by 31.19% to $5.7 million in 2026.
• Business Quant data shows IKT's Total Current Liabilities at $5.7 million in Q1 2026, $8.3 million in Q4 2025, and $6.7 million in Q3 2025.